{Reference Type}: Journal Article
{Title}: Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia.
{Author}: Fang Q;Lu X;Zhu Y;Lv X;Yu F;Ma X;Liu B;Zhang H;
{Journal}: Cell Rep Med
{Volume}: 5
{Issue}: 6
{Year}: 2024 Jun 18
{Factor}: 16.988
{DOI}: 10.1016/j.xcrm.2024.101614
{Abstract}: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor (LDLR) and mediates its internalization and degradation, resulting in an increase in LDL cholesterol levels. Recently, PCSK9 emerged as a therapeutic target for hypercholesterolemia and atherosclerosis. In this study, we develop a PCSK9 nanoparticle (NP) vaccine by covalently conjugating the catalytic domain (aa 153-aa 454, D374Y) of PCSK9 to self-assembled 24-mer ferritin NPs. We demonstrate that the PCSK9 NP vaccine effectively induces interfering antibodies against PCSK9 and reduces serum lipids levels in both a high-fat diet-induced hypercholesterolemia model and an adeno-associated virus-hPCSK9D374Y-induced hypercholesterolemia model. Additionally, the vaccine significantly reduces plaque lesion areas in the aorta and macrophages infiltration in an atherosclerosis mouse model. Furthermore, we discover that the vaccine's efficacy relied on T follicular help cells and LDLR. Overall, these findings suggest that the PCSK9 NP vaccine holds promise as an effective treatment for hypercholesterolemia and atherosclerosis.